pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·30m ago·1 min read
save

WHO advises against obesity drugs for younger children

The World Health Organization on Wednesday recommended against GLP-1 drugs for children with obesity who are under 10 and said adolescents ages 10 to 19 should receive them only after a supervised lifestyle program fails ...

Oct 7, 2026·read at Endpoints ↗

October 7, 2026 02:00 PM EDTUpdated 02:24 PM PharmaGLP-1 drugs WHO ad­vis­es against obe­si­ty drugs for younger chil­dren Maggie Fick The World Health Or­ga­ni­za­tion on Wednes­day rec­om­mend­ed against GLP-1 drugs for chil­dren un­der 10 with obe­si­ty and said ado­les­cents ages 10 to 19 should re­ceive … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
80 words · retrieved 1m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 3h agoBexorg gets $28M ARPA-H award to run longer tests on ‘rebooted’ human brainsEndpoints
  • 3h agoNuvig drops a Phase 2 trial; Cerevance reports Parkinson's progressEndpoints
  • 4h agoNovartis-partnered biotech nabs $150M Series B to move into the clinicEndpoints
  • 6h agoMimiVax's cancer vaccine for glioblastoma narrowly misses Phase 2b goalEndpoints
  • 6h agoTCGX doubles down on China with $600M Asia-focused fundEndpoints